Over recent decades it is encouraging that the UK Government have taken forward a number of initiatives to improve the access to medicines environment. This includes programmes such as the Early Access to Medicines Scheme and the Accelerated Access Collaborative alongside the Cancer Drug Fund.
However, these changes have been introduced gradually and there has been a disconnect in how they interact resulting in a regulatory and access environment for medicines which is complex and confusing, often resulting in delays for patients in accessing new innovations.
2021 is set to be a significant year of reform with the introduction of the Innovative Medicines Fund, and the National Institute for Health and Care Excellence (NICE) Methods Review. These positive developments have the potential to create a real and lasting change by streamlining pathways, helping a greater number of patients live longer.
In this discussion, we are bringing together key thinkers to explore the progress made and what the UK Government and others need to do in order to ensure that the system keeps pace with scientific developments, allowing patients to access innovative medicines quickly.
- Lord Bethell, Minister for Innovation
- Dominic Pivonka, Director of Market Access, AbbVie
- Zack Pemberton-Whiteley, Chair, Blood Cancer Alliance
- Chris Green MP, Chair of the Medical Research APPG and contributor to the Bridging the Gap report (Chair)
Where and when?
Tuesday 26th January 2021 | 10:00 – 11:00 | Webinar
For more information, and to register your interest, please click here.